JP2024513559A5 - - Google Patents

Info

Publication number
JP2024513559A5
JP2024513559A5 JP2023561342A JP2023561342A JP2024513559A5 JP 2024513559 A5 JP2024513559 A5 JP 2024513559A5 JP 2023561342 A JP2023561342 A JP 2023561342A JP 2023561342 A JP2023561342 A JP 2023561342A JP 2024513559 A5 JP2024513559 A5 JP 2024513559A5
Authority
JP
Japan
Prior art keywords
repeat domain
ankyrin repeat
human
binding
binding specificity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023561342A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024513559A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2022/053275 external-priority patent/WO2022215032A1/en
Publication of JP2024513559A publication Critical patent/JP2024513559A/ja
Publication of JP2024513559A5 publication Critical patent/JP2024513559A5/ja
Pending legal-status Critical Current

Links

JP2023561342A 2021-04-09 2022-04-07 新規なDARPinベースのCD70エンゲージャー Pending JP2024513559A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202163173186P 2021-04-09 2021-04-09
US202163172973P 2021-04-09 2021-04-09
US63/173,186 2021-04-09
US63/172,973 2021-04-09
US202163265181P 2021-12-09 2021-12-09
US63/265,181 2021-12-09
PCT/IB2022/053275 WO2022215032A1 (en) 2021-04-09 2022-04-07 Novel darpin based cd70 engagers

Publications (2)

Publication Number Publication Date
JP2024513559A JP2024513559A (ja) 2024-03-26
JP2024513559A5 true JP2024513559A5 (cg-RX-API-DMAC7.html) 2025-04-03

Family

ID=81386901

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023561342A Pending JP2024513559A (ja) 2021-04-09 2022-04-07 新規なDARPinベースのCD70エンゲージャー

Country Status (9)

Country Link
US (1) US20250074994A1 (cg-RX-API-DMAC7.html)
EP (1) EP4319883A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024513559A (cg-RX-API-DMAC7.html)
KR (1) KR20230169182A (cg-RX-API-DMAC7.html)
AU (1) AU2022252985A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023020685A2 (cg-RX-API-DMAC7.html)
CA (1) CA3214020A1 (cg-RX-API-DMAC7.html)
MX (1) MX2023011978A (cg-RX-API-DMAC7.html)
WO (1) WO2022215032A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL298168A (en) 2020-05-14 2023-01-01 Molecular Partners Ag Multispecific proteins
WO2022190016A1 (en) 2021-03-09 2022-09-15 Molecular Partners Ag Novel darpin based multi-specific t-cell engagers
WO2024251628A1 (en) * 2023-06-06 2024-12-12 Molecular Partners Ag Recombinant cd16a binding proteins and their use
JP2026524079A (ja) 2023-06-06 2026-07-17 モレキュラー パートナーズ アクチェンゲゼルシャフト 組換えcd2結合タンパク質及びその使用
WO2025181039A1 (en) 2024-03-01 2025-09-04 Molecular Partners Ag Therapeutic combinations comprising a multi-specific t cell engager

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100150950A1 (en) * 2006-12-14 2010-06-17 Medarex, Inc. Human antibodies that bind cd70 and uses thereof
EP3974453A3 (en) * 2010-11-16 2022-08-03 Amgen Inc. Agents and methods for treating diseases that correlate with bcma expression
EP3514169B1 (en) * 2010-11-26 2024-03-06 Molecular Partners AG Designed repeat proteins binding to serum albumin
JP2016531920A (ja) * 2013-09-05 2016-10-13 アデュロ・バイオテック・ホールディングス・ヨーロッパ・ベスローテン・フエンノートシャップAduro Biotech Holdings, Europe B.V. Cd70結合ペプチドおよびそれに関連する方法、プロセスおよび用途
US9458211B1 (en) * 2015-04-02 2016-10-04 Molecular Partners Ag Recombinant proteins that simultaneously bind HGF, VEGF-A and serum albumin, comprising ankyrin repeat domains
US11291721B2 (en) * 2016-03-21 2022-04-05 Marengo Therapeutics, Inc. Multispecific and multifunctional molecules and uses thereof
MX2020008183A (es) * 2018-02-01 2020-09-22 Pfizer Anticuerpos especificos para cd70 y sus usos.
TW202010757A (zh) * 2018-04-11 2020-03-16 美商英伊布里克斯公司 具有經受限cd3結合的多重特異性多肽構築體以及相關方法及用途
JP2022535564A (ja) * 2019-06-04 2022-08-09 モレキュラー パートナーズ アクチェンゲゼルシャフト 多選択性タンパク質
EP3980452A1 (en) * 2019-06-04 2022-04-13 Molecular Partners AG Recombinant 4-1bb binding proteins and their use
WO2022190016A1 (en) * 2021-03-09 2022-09-15 Molecular Partners Ag Novel darpin based multi-specific t-cell engagers

Similar Documents

Publication Publication Date Title
JP2024508969A5 (cg-RX-API-DMAC7.html)
US12285462B2 (en) pH-triggered membrane peptide-mediated epitope tethering at cell surfaces
US6235716B1 (en) Multivalent ligands which modulate angiogenesis
JP2023506765A5 (cg-RX-API-DMAC7.html)
JP4480580B2 (ja) Wt1置換型ペプチド
JP2023528207A5 (cg-RX-API-DMAC7.html)
JP2010516290A5 (cg-RX-API-DMAC7.html)
JP2005507647A5 (cg-RX-API-DMAC7.html)
CN120939216A (zh) 抗hpv和hpv相关的疾病的新疫苗
RU2017128465A (ru) Неприродные семафорины класса 3 и их медицинское применение
JP2024508683A5 (cg-RX-API-DMAC7.html)
JP2021514661A5 (cg-RX-API-DMAC7.html)
JP2023522588A5 (cg-RX-API-DMAC7.html)
JP2023554379A5 (cg-RX-API-DMAC7.html)
JP2018512124A5 (cg-RX-API-DMAC7.html)
CA2730686A1 (en) Anti-amyloid immunogenic compositions, methods and uses
JP2022535102A5 (cg-RX-API-DMAC7.html)
JP2022507373A5 (cg-RX-API-DMAC7.html)
JP2022513209A (ja) オリゴペプチドを有効成分として含むがんの予防または治療用薬学的組成物
CN115028738B (zh) 一种Fc融合蛋白双重靶向降解剂及应用
JP2022513626A5 (cg-RX-API-DMAC7.html)
JP2022501046A5 (cg-RX-API-DMAC7.html)
JP2025519475A5 (cg-RX-API-DMAC7.html)
JP2022528053A5 (cg-RX-API-DMAC7.html)
WO2017211278A1 (en) Antibody fusion proteins for drug delivery